|
|
L Guedez, W G Stetler-Stevenson, L Wolff, J Wang, P Fukushima, A Mansoor, M Stetler-Stevenson
J Clin Invest. 1998;
102(11):2002
doi:10.1172/JCI2881
Abstract |
Full text
| PDF

C
ellular pathways for induction of programmed cell death (PCD) have been identified, but little is known about specific extracellular matrix processes that may affect apoptosis along those pathways. In this study, a series of Burkitt's lymphoma (BL) cell lines were assayed for their expression of tissue inhibitor of metalloproteinases (TIMP)-1. Results indicate that TIMP-1-positive BL lines show resistance to cold-shock-induced apoptosis. Furthermore, recombinant TIMP-1, but not TIMP-2 or a synthetic metalloproteinase inhibitor (BB-94), confers resistance to apoptosis induced by both CD95-dependent and -independent (cold shock, serum deprivation, and gamma-radiation) pathways in TIMP-1-negative BL lines. TIMP-1 suppression of PCD is not due to metalloproteinase inhibition, as reduction and alkylation of the TIMP-1 did not abolish this activity. Retroviral induction of TIMP-1 not only resulted in cell survival but also in continued DNA synthesis for up to 5 d in the absence of serum, while controls underwent apoptosis. This resistance to apoptosis is reversed by anti-TIMP-1 antibodies, demonstrating that secreted TIMP-1 is active in blocking apoptosis. Furthermore, TIMP-1 upregulation induced expression of Bcl-XL but not Bcl-2 as well as decreased NF-kappaB activity as compared with controls. These results demonstrate that TIMP-1 suppresses apoptosis in B cells and suggests a novel activity for TIMP-1 in tissue homeostasis.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(121)
| Title and authors |
Publication |
Year |
Changes in the Myocardial Interstitium and Contribution to the Progression of Heart Failure
Shaina R. Eckhouse, Francis G. Spinale
|
Heart Failure Clinics
|
2012 |
Matrix metalloproteinases and their inhibitors in canine mammary tumors.
Luca Aresu, Mery Giantin, Emanuela Morello, Marta Vascellari, Massimo Castagnaro, Rosa Lopparelli, Vanessa Zancanella, Anna Granato, Spiridione Garbisa, Arianna Aricò, Alice Bradaschia, Franco Mutinelli, Mauro Dacasto
|
BMC Vet. Res.
|
2011 |
Markers of Progenitor Cell Recruitment and Differentiation Rise Early During Ischemia and Continue During Resuscitation in a Porcine Acute Ischemia Model
Atman P. Shah, Scott T. Youngquist, Christian D. McClung, Ekaterina Tzvetkova, Mohammed A. Hanif, John P. Rosborough, James T. Niemann
|
Journal of Interferon & Cytokine Research
|
2011 |
Matrix metalloproteinase expression during blastema formation in regeneration-competent versus regeneration-deficient amphibian limbs
Neetha Santosh, L. Jack Windsor, Behnaz S. Mahmoudi, Bingbing Li, Weiping Zhang, Ellen A. Chernoff, Nandini Rao, David L. Stocum, Fengyu Song
|
Dev. Dyn.
|
2011 |
Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients
William K. Oh, Roberto Vargas, Susanna Jacobus, Kim Leitzel, Meredith M. Regan, Peter Hamer, Karen Pierce, Sheryl Brown-Shimer, Walter Carney, Suhail M. Ali, Philip W. Kantoff, Allan Lipton
|
Cancer
|
2011 |
Matrix metalloproteinases in tumorigenesis: an evolving paradigm
Hui Hua, Minjing Li, Ting Luo, Yancun Yin, Yangfu Jiang
|
Cell. Mol. Life Sci.
|
2011 |
Comparative study of the immunohistochemical expression of tissue inhibitors of metalloproteinases 1 and 2 between clearly invasive carcinomas and “in situ” trophoblast invasion
Blerta Dimo, Ioannis Ioannidis, Andreas Karameris, George Vilaras, Panagiota Tzoumakari, Aphrodite Nonni, Eystratios Patsouris, Andreas C. Lazaris
|
Med Oncol
|
2011 |
An Alternate Perspective on the Roles of TIMPs and MMPs in Pathology
Craig S. Moore, Stephen J. Crocker
|
Amer J Pathol
|
2011 |
BRAFV600E mutation, TIMP-1 upregulation, and NF- B activation: closing the loop on the papillary thyroid cancer trilogy
A. Bommarito, P. Richiusa, E. Carissimi, G. Pizzolanti, V. Rodolico, G. Zito, A. Criscimanna, F. Di Blasi, M. Pitrone, M. Zerilli
|
Endocrine Related Cancer
|
2011 |
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients
Pernille Braemer Hertel, Dongsheng Tu, Bent Ejlertsen, Maj-Britt Jensen, Eva Balslev, Shan Jiang, Frances P. O’Malley, Kathleen I. Pritchard, Lois E. Shepherd, Annette Bartels
|
Breast Cancer Res Treat
|
2011 |
|